- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02787538
Supporting Patient Care With Electronic Resources in the United States (SuPER-US)
Supporting Patient Care With Electronic Resources in the United States (SuPER-US): Effectiveness of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The proposed project aims to improve the process of making evidence-informed treatment decisions by patients with rheumatoid arthritis (RA) and ultimately empower patient self-management. Current RA treatment emphasizes: 1) the need for early and aggressive treatment, and 2) the use of a treat-to-target approach. However, patients often struggle with treatment decisions, especially when the options have both benefits and risks. To address this challenge, investigators based at Arthritis Research Canada have previously developed an online decision aid called ANSWER-2 (ANimated, Self-serve, WEb-based, Research Tool: Version 2) for RA patients who are considering a biologic, and this tool has been recently adapted for the US healthcare setting (called US-ANSWER-2).
Objectives: 1) To evaluate the effectiveness of US-ANSWER-2 in reducing patients' decisional conflict. 2) To assess the extent to which US-ANSWER-2 improves patients' knowledge about RA medications and confidence in managing their health. 3) To examine the experiences of patients and rheumatologists in using US-ANSWER-2.
The investigators will conduct a proof-of-concept randomized controlled trial with 80 patients with RA. Eligible individuals are those: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic or switching to another biologic, and 3) who have internet access and email. The Intervention Group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own within two days. At the end of the session, a one-page summary will be produced to help them discuss their questions, concerns, and preferred choices with their health care providers. The Control Group will receive a standard online medication guide, reflective of usual practice. Participants will complete the Decisional Conflict Scale (primary outcome) before and after the intervention (US-ANSWER-2 or standard online medication guide). The following secondary outcome measures will be collected at baseline, Month 1, and Month 2: 1) Medication Education Impact Questionnaire, and 2) Partners in Health Scale. In addition, the use of healthcare resources will be collected at baseline and Month 2, and the use of biologics will be collected at Month 6. All participants and their rheumatologists will be invited to participate in a qualitative interview about their experience with the patient decision aid.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Kontakt:
- Sharan Rai, BSc
- E-mail: srai1@mgh.harvard.edu
-
Ledende efterforsker:
- Hyon K Choi, MD, DrPH
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
The inclusion criteria are as follows:
- with a diagnosis of RA from a rheumatologist
- whose rheumatologists have recommended initiating a biologic or switching to another biologic
- who have internet access and email.
Exclusion Criteria:
- Patients who do not meet the inclusion criteria.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: US-ANSWER-2 decision aid
The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days.
At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
|
US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option.
Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
|
Aktiv komparator: Control group (Online medication guide)
The control group will receive the online medication guide, reflective of usual practice.
The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.
|
Standard online medication guide.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Decisional Conflict Scale (DCS)
Tidsramme: Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1)
|
The Decisional Conflict Scale (short version) measures personal perceptions of uncertainty in choosing options, factors contributing to uncertainty, and effective decision-making.
It is one-dimensional and has 10 questions and three response categories (yes/no/unsure) used to compute one score.
|
Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Medication Education Impact Questionnaire (MeiQ)
Tidsramme: Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2
|
The MeiQ consists of 6 subscales and a total of 29 items.
MeiQ was developed and tested in three different samples of patients with rheumatic conditions on their knowledge of medications.
|
Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2
|
Partners in Health Scale (PHS)
Tidsramme: Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2
|
The Partners in Health Scale is an 11-item measure designed to assess self-efficacy, knowledge of RA and treatment, and self-management behaviours such as taking medication appropriately and adopting a healthy lifestyle.
|
Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2
|
Health Resource Utilization (HRU) Questionnaire
Tidsramme: Change measure (baseline score compared to after using the US-ANSWER-2 at Month 2)
|
The HRU questionnaire was developed for both self and interviewer administration in people with arthritis and other chronic conditions.
It consists of a series of open-ended questions about individuals' visits to health professionals, use of investigative tests, hospital visits, use of medications, purchases of adaptive aids, and estimable productivity loss incurred by the individual and their caregivers due to his/her health.
|
Change measure (baseline score compared to after using the US-ANSWER-2 at Month 2)
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Use of biologics
Tidsramme: 6 months from baseline
|
Patients will be asked whether they started or switched a biologic, and the name, since using the US-ANSWER-2.
|
6 months from baseline
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Hyon K Choi, MD, DrPH, Massachusetts General Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2015P002116
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Rheumatoid arthritis
-
Janssen Research & Development, LLCTrukket tilbageAktiv reumatoid arthritis; Rheumatoid arthritis
-
Hamad Medical CorporationUkendtRHEUMATOID ARTHRITISQatar
-
Richard Burt, MDAfsluttet
-
Healthcare Homoeo Charitable SocietyUkendtRheumatoid arthritis.Indien
-
Federal University of São PauloAfsluttetRheumatoid arthritis.Brasilien
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloUkendt- Rheumatoid arthritisBrasilien
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
Biomet Orthopedics, LLCNew Lexington ClinicAfsluttetSlidgigt | Rheumatoid arthritis | Knæ arthritis | Degenerativ arthritisForenede Stater
-
University of SalfordAfsluttetRheumatoid arthritis | Håndslidgigt | Inflammatorisk arthritisDet Forenede Kongerige
-
Link America, Inc.AfsluttetSlidgigt | Rheumatoid arthritis | Post-traumatisk arthritisForenede Stater
Kliniske forsøg med US-ANSWER-2 decision aid
-
Washington University School of MedicineNational Institute on Minority Health and Health Disparities (NIMHD); National...AfsluttetSundhedskompetence | Sygesikring | Sundhedstjenesters tilgængelighed | Informeret beslutningstagningForenede Stater
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI)Afsluttet
-
NYU Langone HealthRekruttering
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RekrutteringAnatomisk fase I brystkræft AJCC v8 | Anatomisk fase IA brystkræft AJCC v8 | Anatomisk fase IB brystkræft AJCC v8 | Anatomisk fase II brystkræft AJCC v8 | Anatomisk fase IIA brystkræft AJCC v8 | Anatomisk fase IIB brystkræft AJCC v8 | Anatomisk fase III brystkræft AJCC v8 | Anatomisk fase IIIA brystkræft... og andre forholdForenede Stater
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyAfsluttet
-
University of Santo Tomas Hospital, PhilippinesPhilippine Council for Health Research & Development; University of Santo... og andre samarbejdspartnereRekrutteringLokalt avanceret livmoderhalskræftFilippinerne
-
Unity Health TorontoAktiv, ikke rekrutterende
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Afsluttet
-
Icahn School of Medicine at Mount SinaiMayo ClinicAfsluttet